These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 16423089

  • 1. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection.
    Cheon JH, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS.
    Helicobacter; 2006 Feb; 11(1):46-51. PubMed ID: 16423089
    [Abstract] [Full Text] [Related]

  • 2. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.
    Kang JM, Kim N, Lee DH, Park YS, Kim YR, Kim JS, Jung HC, Song IS.
    Helicobacter; 2007 Dec; 12(6):623-8. PubMed ID: 18001404
    [Abstract] [Full Text] [Related]

  • 3. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate.
    Yoon H, Kim N, Lee BH, Hwang TJ, Lee DH, Park YS, Nam RH, Jung HC, Song IS.
    Helicobacter; 2009 Oct; 14(5):77-85. PubMed ID: 19751431
    [Abstract] [Full Text] [Related]

  • 4. Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility.
    Cheon JH, Kim SG, Kim JM, Kim N, Lee DH, Kim JS, Jung HC, Song IS.
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1590-5. PubMed ID: 16928222
    [Abstract] [Full Text] [Related]

  • 5. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea.
    Lee BH, Kim N, Hwang TJ, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC, Song IS.
    Helicobacter; 2010 Feb; 15(1):38-45. PubMed ID: 20302588
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
    Zheng Q, Pan Y, Zhang L, Xiao SD.
    Chin J Dig Dis; 2005 Feb; 6(4):202-5. PubMed ID: 16246231
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
    Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, Tsai PY, Wu IC, Wang SW, Li CJ, Weng BC, Chang LL, Jan CM, Wang WM, Wu DC.
    J Antimicrob Chemother; 2009 May; 63(5):1017-24. PubMed ID: 19246508
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
    Kim MS, Kim N, Kim SE, Jo HJ, Shin CM, Park YS, Lee DH.
    BMC Gastroenterol; 2013 Sep 19; 13():138. PubMed ID: 24050512
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
    Nista EC, Candelli M, Zocco MA, Cremonini F, Ojetti V, Finizio R, Spada C, Cammarota G, Gasbarrini G, Gasbarrini A.
    Am J Gastroenterol; 2006 Sep 19; 101(9):1985-90. PubMed ID: 16968503
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
    Uygun A, Ozel AM, Yildiz O, Aslan M, Yesilova Z, Erdil A, Bagci S, Gunhan O.
    J Gastroenterol Hepatol; 2008 Jan 19; 23(1):42-5. PubMed ID: 17559359
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.